Transition Toward Multimodal Integration in Cancer Therapy: Biological Rationales, Clinical Efficacy, and Pharmacological Challenges.

Cancer treatment is increasingly moving beyond single-agent strategies because tumor heterogeneity, clonal evolution, immune escape, and microenvironmental protection frequently limit durable disease control. Existing evidence remains fragmented across cancer types, treatment combinations, sequencing approaches, biomarker systems, and long-term safety outcomes, creating uncertainty regarding which patients benefit most from integrated therapy. This narrative review examines the biological rationale, clinical applications, treatment sequencing, precision tools, toxicity considerations, and implementation challenges associated with multimodal oncology. Relevant literature on surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, cellular therapy, locoregional interventions, liquid biopsy, and artificial intelligence was synthesized thematically. The available evidence indicates that coordinated treatment can improve local and systemic control, delay resistance, enhance immune activation, and support organ-preserving or adaptive strategies in selected malignancies. Benefits are greatest when combinations are mechanistically justified and guided by tumor biology, disease stage, and patient fitness. Major barriers include overlapping toxicity, variable biomarker performance, limited comparative data, financial burden, and unequal access to advanced diagnostics and therapies. Multimodal care should not be equated with indiscriminate treatment intensification. Its future depends on validated predictive markers, optimized sequencing, real-time response monitoring, adaptive trials, and multidisciplinary decision-making. Precision-guided integration is likely to define the next phase of personalized cancer care.